Introduction: anemia in heart failure

Silverberg DS, Wexler D, Blum M et al (2000) The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35:1737–1744 Anand IS (2008) Anemia and chronic heart failure; implications and treatment options. J Am Coll Cardiol 52 (in press) Anand IS (2005) Pathogenesis of anemia in cardiorenal disease. Rev Cardiovasc Med 6(Suppl 3):S13–S21 Phrommintikul A, Haas SJ, Elsik M, Krum H (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369:381–388 FDA A (2008) Additional trials showing increased mortality and/or tumor progression with EPOGEN®/PROCRIT® and Aranesp®. http://www.fda.gov/medwatch/safety/2008/epo_DHCP_03102008.pdf Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris PC (1993) Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J 70:357–362